Cytochrome P450 2D6 and Cytochrome P450 3A4 (CYP2D6 and CYP3A4)

Cytochrome P450 2D6 (CYP2D6) and Cytochrome P450 3A4 (CYP3A4) are the two most clinically significant members of the cytochrome P450 enzyme superfamily, collectively responsible for the Phase I metabolism of approximately 75% of all clinical drugs. CYP3A4 is the most abundant P450 enzyme in the human liver and small intestine, metabolizing roughly 50% of marketed medications, including statins, macrolides, and benzodiazepines (NIH, PubChem). CYP2D6, while less abundant, is highly polymorphic and processes approximately 25% of therapeutic agents, such as antidepressants, beta-blockers, and opioids like codeine (UniProt P10635). These enzymes are essential for xenobiotic detoxification, but their role in activating pro-drugs and clearing active compounds makes them critical determinants of drug safety and efficacy (PubMed 15511347). Genetic variation in CYP2D6 can lead to significantly different metabolic rates, categorized from 'poor' to 'ultrarapid' metabolizers, which necessitates personalized dosing for many psychiatric and cardiovascular drugs (StatPearls NBK545224). Furthermore, because many drugs can inhibit or induce these enzymes, they are the primary source of dangerous drug-drug interactions in clinical practice.

Other names

Debrisoquine 4-hydroxylaseCYPIID6Nifedipine oxidaseCYP3A3HLPCYP3A

These enzymes act as the primary catalysts for the Phase I oxidative metabolism of drugs. Drugs may act as substrates (being metabolized by the enzyme), inhibitors (slowing the metabolism of other drugs), or inducers (increasing the expression and activity of the enzyme).